We conclude that AP-1 drives the chromatin accessibility profile conducive to AP-1/Smad3-dependent nMRTF BCC resistance, and the identified surface proteins can act as prognostic markers for response rate to AP-1 inhibitors. The gene discussed is JUNB; the disease is skin basal cell carcinoma.